Evidence map›Paper›PMID 29530939›Full record

ArticleDevelopment (Cambridge, England)2018

Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium.

Michael Lie-A-Ling, Elli Marinopoulou, Andrew J Lilly, Mairi Challinor, Rahima Patel, Christophe Lancrin, Valerie Kouskoff, Georges Lacaud

Open access · hybridAbstract read
In one paragraph

Article in Development (Cambridge, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Endothelial Cell Differentiation and Hemogenic Specification.Cold Spring Harbor perspectives in medicine · 2022
    Review
  12. Article
  13. Hemogenic and aortic endothelium arise from a common hemogenic angioblast precursor and are specified by the Etv2 dosage.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Michael Lie-A-LingStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
Elli MarinopoulouStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
Andrew J LillyStem Cell Hematopoiesis, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
Mairi ChallinorStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
Rahima PatelStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
Christophe LancrinEMBL Rome, Epigenetics and Neurobiology Unit, Campus Adriano Buzzati-Traverso Via Ramarini 32, 00015 Monterotondo, Italy.
Valerie KouskoffStem Cell Hematopoiesis, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK georges.lacaud@cruk.manchester.ac.uk Valerie.kouskoff@manchester.ac.uk.ORCID 0000-0001-9801-4993
Georges LacaudStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Wilmslow Road, Manchester M20 4BX, UK georges.lacaud@cruk.manchester.ac.uk Valerie.kouskoff@manchester.ac.uk.ORCID 0000-0002-5630-2417
University of Manchester · GBEuropean Molecular Biology Laboratory · IT

Funding

Biotechnology and Biological Sciences Research Council BB/I001794/1Cancer Research UK 12486Cancer Research UK 12487Cancer Research UK 19565Cancer Research UK C5759/A20971Medical Research Council MR/P000673/1Wellcome Trust
6 · The paper itself

Abstract

During ontogeny, hematopoietic stem and progenitor cells arise from hemogenic endothelium through an endothelial-to-hematopoietic transition that is strictly dependent on the transcription factor RUNX1. Although it is well established that RUNX1 is essential for the onset of hematopoiesis, little is known about the role of RUNX1 dosage specifically in hemogenic endothelium and during the endothelial-to-hematopoietic transition. Here, we used the mouse embryonic stem cell differentiation system to determine if and how RUNX1 dosage affects hemogenic endothelium differentiation. The use of inducible

Indexed as

AnimalsCell DifferentiationCells, CulturedCore Binding Factor Alpha 2 SubunitEndothelium, VascularGene DosageGene Expression RegulationHemangioblastsHematopoiesisHematopoietic Stem CellsMiceMice, KnockoutCore Binding Factor Alpha 2 SubunitRunx1 protein, mouseCBFβDosageEHTHemogenic endotheliumRUNX1SOX7

Identifiers

PMID29530939
PMCPMC5868988
OpenAlexW2787198874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.